Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2011, Article ID 865432, 8 pages
http://dx.doi.org/10.4061/2011/865432
Review Article

Possible Role of the Transglutaminases in the Pathogenesis of Alzheimer's Disease and Other Neurodegenerative Diseases

Department of Biochemistry and Biophysics, Second University of Naples, Via Costantinopoli 16, 80138 Naples, Italy

Received 23 November 2010; Accepted 5 January 2011

Academic Editor: Brian J. Balin

Copyright © 2011 Antonio Martin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. E. Folk, “Mechanism and basis for specificity of transglutaminase-catalyzed epsilon-(gamma-glutamyl) lysine bond formation,” Advances in Enzymology and Related Areas of Molecular Biology, vol. 54, pp. 1–56, 1983. View at Google Scholar · View at Scopus
  2. L. Lorand and S. M. Conrad, “Transglutaminases,” Molecular and Cellular Biochemistry, vol. 58, no. 1-2, pp. 9–35, 1984. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Piacentini, N. Martinet, S. Beninati, and J. E. Folk, “Free and protein-conjugated polyamines in mouse epidermal cells. Effect of high calcium and retinoic acid,” Journal of Biological Chemistry, vol. 263, no. 8, pp. 3790–3794, 1988. View at Google Scholar · View at Scopus
  4. C. Y. Kim, H. Quarsten, E. Bergseng, C. Khosla, and L. M. Sollid, “Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 12, pp. 4175–4179, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. B. Fleckenstein, S. W. Qiao, M. R. Larsen, G. Jung, P. Roepstorff, and L. M. Sollid, “Molecular characterization of covalent complexes between tissue transglutaminase and gliadin peptides,” Journal of Biological Chemistry, vol. 279, no. 17, pp. 17607–17616, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. K. E. Achyuthan and C. S. Greenberg, “Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity,” Journal of Biological Chemistry, vol. 262, no. 4, pp. 1901–1906, 1987. View at Google Scholar · View at Scopus
  7. G. Hasegawa, M. Suwa, Y. Ichikawa et al., “A novel function of tissue-type transglutaminase: protein disulphide isomerase,” Biochemical Journal, vol. 373, no. 3, pp. 793–803, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. J. Lahav, E. Karniel, Z. Bagoly, V. Sheptovitsky, R. Dardik, and A. Inbal, “Coagulation factor XIII serves as protein disulfide isomerase,” Thrombosis and Haemostasis, vol. 101, no. 5, pp. 840–844, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. S. E. Iismaa, B. M. Mearns, L. Lorand, and R. M. Graham, “Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders,” Physiological Reviews, vol. 89, no. 3, pp. 991–1023, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. B. Olaisen, T. Gedde-Dahl Jr., and P. Teisberg, “A structural locus for coagulation factor XIIIA (F13A) is located distal to the HLA region on chromosome 6p in man,” American Journal of Human Genetics, vol. 37, no. 1, pp. 215–220, 1985. View at Google Scholar
  11. K. Yamanishi, J. Inazawa, F. M. Liew et al., “Structure of the gene for human transglutaminase 1,” Journal of Biological Chemistry, vol. 267, no. 25, pp. 17858–17863, 1992. View at Google Scholar
  12. V. Gentile, P. J. A. Davies, and A. Baldini, “The human tissue transglutaminase gene maps on chromosome 20q12 by in situ fluorescence hybridization,” Genomics, vol. 20, no. 2, pp. 295–297, 1994. View at Publisher · View at Google Scholar · View at PubMed
  13. M. Wang, I. G. Kim, P. M. Steinert, and O. W. McBride, “Assignment of the human transglutaminase 2 (TGM2) and transglutaminase 3 (TGM3) genes to chromosome 20q11.2,” Genomics, vol. 23, no. 3, pp. 721–722, 1994. View at Publisher · View at Google Scholar · View at PubMed
  14. V. Gentile, F. J. Grant, R. Porta, and A. Baldini, “Localization of the human prostate transglutaminase (type IV) gene (TGM4) to chromosome 3p21.33-p22 by fluorescence in situ hybridization,” Genomics, vol. 27, no. 1, pp. 219–220, 1995. View at Publisher · View at Google Scholar · View at PubMed
  15. P. Grenard, M. K. Bates, and D. Aeschlimann, “Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15: structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z,” Journal of Biological Chemistry, vol. 276, no. 35, pp. 33066–33078, 2001. View at Publisher · View at Google Scholar · View at PubMed
  16. P. A. Smethurst and M. Griffin, “Measurement of tissue transglutaminase activity in a permeabilized cell system: its regulation by Ca2+ and nucleotides,” Biochemical Journal, vol. 313, no. 3, pp. 803–808, 1996. View at Google Scholar
  17. H. Nakaoka, D. M. Perez, K. J. Baek et al., “Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function,” Science, vol. 264, no. 5165, pp. 1593–1596, 1994. View at Google Scholar
  18. V. Gentile, R. Porta, E. Chiosi et al., “tTGase/Gαh protein expression inhibits adenylate cyclase activity in Balb-C 3T3 fibroblasts membranes,” Biochimica et Biophysica Acta, vol. 1357, no. 1, pp. 115–122, 1997. View at Publisher · View at Google Scholar
  19. N. Nanda, S. E. Iismaa, W. A. Owens, A. Husain, F. Mackay, and R. M. Graham, “Targeted inactivation of G/tissue transglutaminase II,” Journal of Biological Chemistry, vol. 276, no. 23, pp. 20673–20678, 2001. View at Publisher · View at Google Scholar · View at PubMed
  20. S. Mian, S. El Alaoui, J. Lawry, V. Gentile, P. J. A. Davies, and M. Griffin, “The importance of the GTP-binding protein tissue transglutaminase in the regulation of cell cycle progression,” FEBS Letters, vol. 370, no. 1-2, pp. 27–31, 1995. View at Publisher · View at Google Scholar
  21. V. Thomazy and L. Fesus, “Differential expression of tissue transglutaminase in human cells. An immunohistochemical study,” Cell and Tissue Research, vol. 255, no. 1, pp. 215–224, 1989. View at Google Scholar
  22. C. D. C. Bailey and G. V. W. Johnson, “Developmental regulation of tissue transglutaminase in the mouse forebrain,” Journal of Neurochemistry, vol. 91, no. 6, pp. 1369–1379, 2004. View at Publisher · View at Google Scholar · View at PubMed
  23. S. Y. Kim, P. Grant, J. H. Lee, H. C. Pant, and P. M. Steinert, “Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease,” Journal of Biological Chemistry, vol. 274, no. 43, pp. 30715–30721, 1999. View at Publisher · View at Google Scholar
  24. B. A. Citron, K. S. SantaCruz, P. J. A. Davies, and B. W. Festoff, “Intron-exon swapping of transglutaminase mRNA and neuronal tau aggregation in Alzheimer's disease,” Journal of Biological Chemistry, vol. 276, no. 5, pp. 3295–3301, 2001. View at Publisher · View at Google Scholar · View at PubMed
  25. V. De Laurenzi and G. Melino, “Gene disruption of tissue transglutaminase,” Molecular and Cellular Biology, vol. 21, no. 1, pp. 148–155, 2001. View at Publisher · View at Google Scholar · View at PubMed
  26. L. Lorand and R. M. Graham, “Transglutaminases: crosslinking enzymes with pleiotropic functions,” Nature Reviews Molecular Cell Biology, vol. 4, no. 2, pp. 140–156, 2003. View at Publisher · View at Google Scholar · View at PubMed
  27. R. D. Adams and M. Victor, Principles of Neurology, McGraw-Hill, New York, NY, USA, 1993.
  28. D. J. Selkoe, Y. Ihara, and F. J. Salazar, “Alzheimer's disease: insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea,” Science, vol. 215, no. 4537, pp. 1243–1245, 1982. View at Google Scholar
  29. A. J. Grierson, G. V. W. Johnson, and C. C. J. Miller, “Three different human tau isoforms and rat neurofilament light, middle and heavy chain proteins are cellular substrates for transglutaminase,” Neuroscience Letters, vol. 298, no. 1, pp. 9–12, 2001. View at Publisher · View at Google Scholar
  30. S. M. Dudek and G. V. W. Johnson, “Transglutaminase catalyzes the formation of sodium dodecyl sulfate-insoluble, Alz-50-reactive polymers of τ,” Journal of Neurochemistry, vol. 61, no. 3, pp. 1159–1162, 1993. View at Google Scholar
  31. M. L. Miller and G. V. W. Johnson, “Transglutaminase cross-linking of the τ protein,” Journal of Neurochemistry, vol. 65, no. 4, pp. 1760–1770, 1995. View at Google Scholar
  32. D. M. Appelt and B. J. Balin, “The association of tissue transglutaminase with human recombinant tau results in the formation of insoluble filamentous structures,” Brain Research, vol. 745, no. 1-2, pp. 21–31, 1997. View at Publisher · View at Google Scholar
  33. S. M. Singer, G. M. Zainelli, M. A. Norlund, J. M. Lee, and N. A. Muma, “Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease,” Neurochemistry International, vol. 40, no. 1, pp. 17–30, 2002. View at Publisher · View at Google Scholar
  34. D. M. Appelt, G. C. Kopen, L. J. Boyne, and B. J. Balin, “Localization of transglutaminase in hippocampal neurons: implications for Alzheimer's disease,” Journal of Histochemistry and Cytochemistry, vol. 44, no. 12, pp. 1421–1427, 1996. View at Google Scholar
  35. B. J. Balin, A. G. Loewy, and D. M. Appelt, “Analysis of transglutaminase-catalyzed isopeptide bonds in paired helical filaments and neurofibrillary tangles from Alzheimer's disease,” Methods in Enzymology, vol. 309, pp. 172–186, 1999. View at Publisher · View at Google Scholar
  36. M. M. M. Wilhelmus, S. C. S. Grunberg, J. G. J. M. Bol et al., “Transglutaminases and transglutaminase-catalyzed cross-links colocalize with the pathological lesions in Alzheimer's disease brain,” Brain Pathology, vol. 19, no. 4, pp. 612–622, 2009. View at Publisher · View at Google Scholar · View at PubMed
  37. T. M. Jeitner, W. R. Matson, J. E. Folk, J. P. Blass, and A. J. L. Cooper, “Increased levels of γ-glutamylamines in Huntington disease CSF,” Journal of Neurochemistry, vol. 106, no. 1, pp. 37–44, 2008. View at Publisher · View at Google Scholar · View at PubMed
  38. S. M. Dudek and G. V. W. Johnson, “Transglutaminase facilitates the formation of polymers of the β-amyloid peptide,” Brain Research, vol. 651, no. 1-2, pp. 129–133, 1994. View at Publisher · View at Google Scholar
  39. D. M. Hartley, C. Zhao, A. C. Speier et al., “Transglutaminase induces protofibril-like amyloid β-protein assemblies that are protease-resistant and inhibit long-term potentiation,” Journal of Biological Chemistry, vol. 283, no. 24, pp. 16790–16800, 2008. View at Publisher · View at Google Scholar · View at PubMed
  40. B. A. Citron, Z. Suo, K. SantaCruz, P. J. A. Davies, F. Qin, and B. W. Festoff, “Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration,” Neurochemistry International, vol. 40, no. 1, pp. 69–78, 2002. View at Publisher · View at Google Scholar
  41. E. Junn, R. D. Ronchetti, M. M. Quezado, S. Y. Kim, and M. M. Mouradian, “Tissue transglutaminase-induced aggregation of α-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 4, pp. 2047–2052, 2003. View at Publisher · View at Google Scholar · View at PubMed
  42. M. O. Zemaitaitis, J. M. Lee, J. C. Troncoso, and N. A. Muma, “Transglutaminase-induced cross-linking of tau proteins in progressive supranuclear palsy,” Journal of Neuropathology and Experimental Neurology, vol. 59, no. 11, pp. 983–989, 2000. View at Google Scholar
  43. M. O. Zemaitaitis, S. Y. Kim, R. A. Halverson, J. C. Troncoso, J. M. Lee, and N. A. Muma, “Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy,” Journal of Neuropathology and Experimental Neurology, vol. 62, no. 2, pp. 173–184, 2003. View at Google Scholar
  44. S. Iuchi, G. Hoffner, P. Verbeke, P. Djian, and H. Green, “Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 5, pp. 2409–2414, 2003. View at Publisher · View at Google Scholar · View at PubMed
  45. V. Gentile, C. Sepe, M. Calvani et al., “Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases,” Archives of Biochemistry and Biophysics, vol. 352, no. 2, pp. 314–321, 1998. View at Publisher · View at Google Scholar · View at PubMed
  46. P. Kahlem, H. Green, and P. Djian, “Transglutaminase action imitates Huntington's disease: selective polymerization of huntingtin containing expanded polyglutamine,” Molecular Cell, vol. 1, no. 4, pp. 595–601, 1998. View at Google Scholar
  47. M. V. Karpuj, H. Garren, H. Slunt et al., “Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 13, pp. 7388–7393, 1999. View at Publisher · View at Google Scholar
  48. L. G. Verhoef, K. Lindsten, M. G. Masucci, and N. P. Dantuma, “Aggregate formation inhibits proteasomal degradation of polyglutamine proteins,” Human Molecular Genetics, vol. 11, no. 22, pp. 2689–2700, 2002. View at Google Scholar
  49. M. E. MacDonald, C. M. Ambrose, M. P. Duyao et al., “A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes,” Cell, vol. 72, no. 6, pp. 971–983, 1993. View at Publisher · View at Google Scholar
  50. S. Banfi, M. Y. Chung, T. J. Kwiatkowski et al., “Mapping and cloning of the critical region for the spinocerebellar ataxia type 1 gene (SCA1) in a yeast artificial chromosome contig spanning 1.2 Mb,” Genomics, vol. 18, no. 3, pp. 627–635, 1993. View at Publisher · View at Google Scholar
  51. K. Sanpei, H. Takano, S. Igarashi et al., “Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT,” Nature Genetics, vol. 14, no. 3, pp. 277–284, 1996. View at Google Scholar
  52. M. A. Pujana, V. Volpini, and X. Estivill, “Large CAG/CTG repeat templates produced by PCR, usefulness for the DIRECT method of cloning genes with CAG/CTG repeat expansions,” Nucleic Acids Research, vol. 26, no. 5, pp. 1352–1353, 1998. View at Publisher · View at Google Scholar
  53. C. F. Fletcher, C. M. Lutz, T. N. O'Sullivan et al., “Absence epilepsy in tottering mutant mice is associated with calcium channel defects,” Cell, vol. 87, no. 4, pp. 607–617, 1996. View at Publisher · View at Google Scholar
  54. J. B. Vincent, M. L. Neves-Pereira, A. D. Paterson et al., “An unstable trinucleotide-repeat region on chromosome 13 implicated in spinocerebellar ataxia: a common expansion locus,” American Journal of Human Genetics, vol. 66, no. 3, pp. 819–829, 2000. View at Publisher · View at Google Scholar · View at PubMed
  55. S. E. Holmes, E. O'Hearn, and R. L. Margolis, “Why is SCA12 different from other SCAs?” Cytogenetic and Genome Research, vol. 100, no. 1-4, pp. 189–197, 2003. View at Publisher · View at Google Scholar · View at PubMed
  56. G. Imbert, Y. Trottier, J. Beckmann, and J. L. Mandel, “The gene for the TATA binding protein (TBP) that contains a highly polymorphic protein coding CAG repeat maps to 6q27,” Genomics, vol. 21, no. 3, pp. 667–668, 1994. View at Publisher · View at Google Scholar · View at PubMed
  57. A. R. La Spada, E. M. Wilson, D. B. Lubahn, A. E. Harding, and K. H. Fischbeck, “Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy,” Nature, vol. 352, no. 6330, pp. 77–79, 1991. View at Publisher · View at Google Scholar · View at PubMed
  58. O. Onodera, M. Oyake, H. Takano, T. Ikeuchi, S. Igarashi, and S. Tsuji, “Molecular cloning of a full-length cDNA for dentatorubral-pallidoluysian atrophy and regional expressions of the expanded alleles in the CNS,” American Journal of Human Genetics, vol. 57, no. 5, pp. 1050–1060, 1995. View at Google Scholar
  59. O. W. Griffith, A. Larsson, and A. Meister, “Inhibition of γ-glutamylcysteine synthetase by cystamine; an approach to a therapy of 5-oxoprolinuria (pyroglutamic aciduria),” Biochemical and Biophysical Research Communications, vol. 79, no. 3, pp. 919–925, 1977. View at Google Scholar
  60. S. Igarashi, R. Koide, T. Shimohata et al., “Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch,” Nature Genetics, vol. 18, no. 2, pp. 111–117, 1998. View at Publisher · View at Google Scholar · View at PubMed
  61. M. V. Karpuj, M. W. Becher, J. E. Springer et al., “Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine,” Nature Medicine, vol. 8, no. 2, pp. 143–149, 2002. View at Publisher · View at Google Scholar · View at PubMed
  62. A. Dedeoglu, J. K. Kubilus, T. M. Jeitner et al., “Therapeutic effects of cystamine in a murine model of Huntington's disease,” Journal of Neuroscience, vol. 22, no. 20, pp. 8942–8950, 2002. View at Google Scholar
  63. M. Lesort, M. Lee, J. Tucholski, and G. V. W. Johnson, “Cystamine inhibits caspase activity: implications for the treatment of polyglutamine disorders,” Journal of Biological Chemistry, vol. 278, no. 6, pp. 3825–3830, 2003. View at Publisher · View at Google Scholar · View at PubMed
  64. M. Hadjivassiliou, P. Aeschlimann, A. Strigun, D. S. Sanders, N. Woodroofe, and D. Aeschlimann, “Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase,” Annals of Neurology, vol. 64, no. 3, pp. 332–343, 2008. View at Publisher · View at Google Scholar · View at PubMed
  65. B. F. Krasnikov, S. Y. Kim, S. J. McConoughey et al., “Transglutaminase activity Is present in highly purified nonsynaptosomal mouse brain and liver mitochondria,” Biochemistry, vol. 44, no. 21, pp. 7830–7843, 2005. View at Publisher · View at Google Scholar · View at PubMed
  66. P. G. Mastroberardino, C. Iannicola, R. Nardacci et al., “'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease,” Cell Death and Differentiation, vol. 9, no. 9, pp. 873–880, 2002. View at Publisher · View at Google Scholar · View at PubMed
  67. J. E. Davies, C. Rose, S. Sarkar, and D. C. Rubinsztein, “Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy,” Science Translational Medicine, vol. 2, no. 34, pp. 34–40, 2010. View at Publisher · View at Google Scholar · View at PubMed